undamentalytics Newsletter

Biofrontera Inc. cash flow statement

In fiscal 2025, Biofrontera Inc.'s operations generated −$13.4m of cash; it spent $2,000 on capital projects, leaving free cash flow of −$13.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biofrontera Inc.: cash flow statement, annual
Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−12−27−16−25−10−13−8
Depreciation and amortisation0001000
Stock-based pay—021111
Capital spending——00000
Free cash flow——−16−25−10−13−8
Free cash flow after stock pay——−18−26−11−14−9
Shares issued—15958——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BFRI vs CPIXAQST vs BFRIBFRI vs IMCC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Biofrontera Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biofrontera Inc.